$IRLA

IRulya Therapeutics (IRLA) released an updated corporate presentation with LAM-001 Phase 2 clinical data, including 6MWD +67.4m, PVR -35.3%, and NT-proBNP -28.8% at 24 weeks. Phase 2b PH-ILD data is expected in 1Q 2028, and Phase 2 BOS data in 1Q 2027. The company plans a Phase 2 SAPH trial starting 4Q 2026 with data anticipated in 4Q 2028. IRLA also highlighted its IP strategy and exclusivity plans.

Quince Therapeutics, Inc. (QNCX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease Company common stock to trade on Nasdaq under the symbol “IRLA” effective October 12, 2026 Key Management changes i

Raymond James initiated coverage on Quince Therapeutics (NASDAQ:QNCX) with an outperform rating and $72 price target, citing its LAM-001 drug for pulmonary diseases. The stock trades near its $30.41 fair value, with a $29.86M market cap and no expected profitability this year. Other analysts also gave positive ratings and targets. The company plans a stockholder meeting to vote on issuing shares, potentially changing control. LAM-001 remains a key focus.

Quince Therapeutics, Inc. (QNCX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 6, 2026, Quince Therapeutics, Inc. (the “ Company ”), held a special meeting of stockholders (the “ Special Mee

Quince Therapeutics, Inc. (QNCX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 30, 2026, each of June Bray, David Lamond and Christopher Senner (collectively, the “ Resigning Directors ”)

Citizens upgraded Quince Therapeutics (QNCX) to Market Outperform with a $77 price target, citing its rare disease pipeline and undervaluation. The company's LAM-001 drug is in Phase 2 trials for pulmonary diseases, with a potential market of 200,000 patients in the U.S. and Europe. QNCX shares have risen ~94% in six months, and the company plans a stockholder meeting to vote on share issuance.

Quince Therapeutics, Inc. (QNCX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION Quince Therapeutics, Inc., a Delaware corporation (the "Company” or "Seller"), Quince Therapeutics SpA, a company organized under the laws of Italy ("Quince SPA", "Italian Subsidiary") entered into an a

Quince Therapeutics' President Charles Ryan will leave the company on September 8, 2026, according to an SEC filing. The reason for his departure and any replacement details were not disclosed.

Quince Therapeutics, Inc. (QNCX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 23, 2026, Quince Therapeutics, Inc. (the “Company”) and Charles Ryan, the Company’s President, determined that M

Quince Therapeutics (Nasdaq: QNCX) reported Q2 2026 results and a corporate update. It completed the stock-for-stock acquisition of Orphai, adding inhaled rapamycin LAM-001 to its pipeline. Quince closed a $115M private placement, with up to $83M more via warrants. Cash was $116M at June 30, 2026, funding operations through end-2028. Net loss was $75.5M.